Literature DB >> 9476583

Angiotensin II promotes remodelling-related events in cardiac fibroblasts.

T Nunohiro1, N Ashizawa, K Graf, Y S Do, W A Hsueh, K Yano.   

Abstract

Remodelling is a fundamental cardiac response to injury, and involves cardiac fibroblast proliferation and extracellular matrix production. Angiotensin II (A II) directly promotes these changes in cardiac fibroblasts, and is thus a critical element in cardiac hypertrophy and a processor of wound healing. Osteopontin mRNA was readily detectable in total RNA harvested from cultured neonatal and adult cardiac fibroblasts. Immunocytochemical staining of cultured adult cardiac fibroblasts grown on coverslips revealed the presence of beta 3 integrin on the surfaces of the cells. In the present study, we investigated the role of A II in a model of wound healing using floating collagen gels harboring adult rat cardiac fibroblasts. The presence of a monoclonal antibody against osteopontin, MPIIIB10, at 7.2 micrograms/ml, or the arginine-glycine-aspartate (RGD) peptide (10(-4) M), had no effect on gel contraction. Osteopontin itself induced fibroblast gel contraction (79.1 +/- 3.8%). But this effect of osteopontin was completely neutralized by MPIIIB10 (7.2 micrograms/ml), RGD peptide (10(-4) M), and monoclonal antibody against rat beta 3 integrin (25 micrograms/ml). These results suggest that A II promotes cardiac wound healing and remodelling processes by inducing osteopontin and beta 3 integrin in cardiac fibroblasts.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9476583

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  3 in total

1.  Possible roles of mast cell-derived chymase for skin rejuvenation.

Authors:  Nobuyuki Amano; Shinji Takai; Denan Jin; Koichi Ueda; Mizuo Miyazaki
Journal:  Lasers Med Sci       Date:  2008-04-12       Impact factor: 3.161

2.  Reduced serum content and increased matrix stiffness promote the cardiac myofibroblast transition in 3D collagen matrices.

Authors:  Peter A Galie; Margaret V Westfall; Jan P Stegemann
Journal:  Cardiovasc Pathol       Date:  2011-02-08       Impact factor: 2.185

3.  Plasma Osteopontin Levels and Adverse Cardiovascular Outcomes in the PEACE Trial.

Authors:  Ahmed D Abdalrhim; Tariq S Marroush; Erin E Austin; Bernard J Gersh; Nusret Solak; Syed A Rizvi; Kent R Bailey; Iftikhar J Kullo
Journal:  PLoS One       Date:  2016-06-10       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.